We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 30, 2014
Last Update Posted: November 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
NuSirt Biopharma
The goal of this study is to demonstrate that leucine in combination with a low does of metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in type 2 diabetic subjects. This study will compare three doses of a leucine-metformin combination to the standard metformin dose in controlling blood glucose levels in type 2 diabetic patients.

Condition Intervention Phase
Type 2 Diabetes Mellitus Drug: Low Metformin Drug: Metformin Drug: Mid Metformin Drug: High Metformin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by NuSirt Biopharma:

Primary Outcome Measures:
  • Change In Fasting Plasma Glucose [ Time Frame: Baseline, Day 28 ]
    Fasting plasma glucose levels will be measured in a variety of ways including; Standard fasting plasma glucose lab readings, seven point glucose profiles, and through continuous glucose monitoring.

Secondary Outcome Measures:
  • Gastrointestinal Effects [ Time Frame: Baseline, Day 28 ]
    Effects on gastrointestinal symptoms patients experienced by questions answered.

  • Change in Baseline-Corrected Plasma Glucose and Insulin Area Under The Concentration Curves [ Time Frame: Baseline, Day 28 ]
    Plasma blood glucose levels will be accessed through continuous glucose monitoring and through standard 3 hour meal tolerance tests.

  • Change in Insulin Secretory Rates [ Time Frame: Baseline, Day 28 ]
    Insulin secretory rates will be tested using standard 3 hour meal tolerance testing.

  • Change in Fasting Plasma Lipids [ Time Frame: Baseline, Day 28 ]
    Fasting plasmid lipids will be tested by standard lipid chemistry

  • Change in HbA1c [ Time Frame: Baseline, Day 28 ]
    HbA1c will be examined through standard chemistry

  • Change in HOMA-IR [ Time Frame: Baseline, Day 28 ]
    HOMA-IR will be evaluated through standard chemistry

  • Change In 7-Point Glucose Profiles [ Time Frame: Baseline, Day 7, Day 21, Day 28 ]
    7 point glucose profiles will be examined by obtaining plasma glucose levels at 7 different time points

  • Change In Serial Blood Glucose Concentrations [ Time Frame: Baseline,Day 28 ]
    Assessed by continuous glucose monitoring

  • Safety and Tolerability [ Time Frame: Baseline, Day 28 ]
    Patients will be monitored and asked about any adverse events or problems they encounter as a result of the study drug

Enrollment: 96
Study Start Date: July 2014
Study Completion Date: January 2016
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
Drug: Low Metformin
1100 mg L Leucine in combination with 125 mg of Metformin BID
Other Names:
  • Metformin
  • Leucine
  • L-Leucine
Experimental: Mid Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
Drug: Mid Metformin
1100 mg of Leucine in combination with 250 mg Metformin BID
Other Names:
  • Metformin
  • Leucine
  • L-Leucine
Experimental: High Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
Drug: High Metformin
1100 mg of Leucine in combination with 500 mg Metformin BID
Other Names:
  • Metformin
  • Leucine
  • L-Leucine
Experimental: Metformin Monotherapy
3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
Drug: Metformin
500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID

Detailed Description:

This is a randomized, 4-week, active-controlled, double-blind study to evaluate the effect of various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control. In this study, standard metformin therapy will be defined as 1000 g/day for Day 1 to Day 14 and then escalated to 1700 g/day for Day 15 to Day 28. Subjects meeting all inclusion criteria and no exclusion criteria will be randomized to one of four treatment arms.

The primary objective of the study is to evaluate the change in fasting plasma glucose from Baseline (Day 1) to Week 4 (Day 28) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy. Secondary objectives will also assess changes in baseline-corrected plasma glucose and insulin area under the concentration curves from baseline to day 28 and changes in insulin secretory rates as assessed during a 3-hour meal tolerance test. Finally the effects of gastrointestinal symptoms will be assessed by subject questionnaires.

The study will include a total of 3 periods: screening or washout of current diabetic monotherapy, a pre-treatment period to ensure subjects will be compliant, and a treatment period of 4 weeks, with the first dosing of medication on day 1 of the study. Each day blood glucose readings will be measured and recorded by patients. Three-hour standardized meal tests will be performed at Baseline (Day 1) and at Study Termination (Day 28). In addition, two, 7-day continuous glucose assessments will be conducted, as well as two seven point glucose profiles. Patients will also be asked about any gastrointestinal side effects they experience.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Over age 18 at study entry.
  • Male, or female, if female, meets all of the following criteria:
  • Not breastfeeding
  • Post-menopausal or negative pregnancy test result (human chorionic gonadotropin, beta subunit [β- hCG]) at Screening (Visit 1) (not required for hysterectomized females)
  • If of childbearing potential and sexually active, must practice and be willing to continue to practice appropriate birth control
  • Is diagnosed with type 2 diabetes mellitus and either not adequately controlled by: diet and exercise alone or diet and exercise plus a single, first line treatment for type 2 diabetes.
  • If treated with an oral anti-diabetes agent, be willing and able to withdraw from therapy for 4 weeks after the screening visit and prior to initiating study mediation at Baseline (Day 1/Visit 4).
  • Be willing to avoid acetaminophen use for intervals up to 10 days as required for study procedures (see Section 4.6)
  • Has a fasting plasma glucose ≥126 mg/dL to ≤220 mg/dL at Screening
  • Has an HbA1c ≥7% to ≤8.5% at Screening
  • Has a BMI ≤40 kg/m2
  • Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either normal or abnormal but consistent with type 2 diabetes mellitus.
  • Is able to read, understand, and sign the informed consent forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.

Exclusion Criteria:

  • Clinically significant renal dysfunction
  • If using any of the following medications, has not been on a stable treatment regimen for a minimum of 4 weeks prior to screening:

Lipid-lowering agents Anti-hypertensive medications Thyroid replacement therapy Non-steroidal anti-inflammatory agents

  • Unable to perform self-blood glucose monitoring employing a glucose meter.
  • History of active cardio- or cerebro-vascular disease with an event within the previous 6 months
  • Gastrointestinal disorders
  • Endocrine disorders other than type 2 diabetes
  • Chronic infection
  • Hepatic disease
  • Neurological or psychiatric diseases
  • History of other psychiatric disorders
  • Has been treated (within the last month), is currently treated, or is expected to require or undergo treatment with; any anti-diabetes medications (other than as allowed by the inclusion criteria), oral or parenteral steroids.
  • Participation in a weight loss program within the past 3 months.
  • Weight change by more than 10 pounds during the past month.
  • History of alcohol or substance abuse in the past 3 months or a positive screen for alcohol or drugs of abuse at screening.
  • Has received any investigational drug within 3 months of Screening.
  • Has donated blood within 3 months before Screening or is planning to donate blood during the study.
  • Has known allergies or hypersensitivity to metformin or leucine
  • Is employed, contracted or has an immediate family member directly affiliated with NuSirt Biopharma.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02151461

United States, California
Catalina Research Institute
Chino, California, United States, 91710
United States, Florida
Palm Beach Research
Palm Beach, Florida, United States, 33409
Meridien Research
Tampa, Florida, United States, 33606
United States, Georgia
River Birch Research Alliance
Blue Ridge, Georgia, United States, 30513
Meridian Research
Savannah, Georgia, United States, 31406
United States, Ohio
Streling Research Group
Cincinnati, Ohio, United States, 45219
United States, South Carolina
Medical Research South
Charleston, South Carolina, United States, 29407
United States, Tennessee
Meharry Medical College
Nashville, Tennessee, United States, 37208
Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
NuSirt Biopharma
Study Chair: Orville G Kolterman, MD NuSirt Biopharma
  More Information

Responsible Party: NuSirt Biopharma
ClinicalTrials.gov Identifier: NCT02151461     History of Changes
Other Study ID Numbers: NS-0100-01
First Submitted: May 28, 2014
First Posted: May 30, 2014
Last Update Posted: November 13, 2017
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: plan to share clinical data July 2017 on clinical trial.gov

Keywords provided by NuSirt Biopharma:
Type 2 Diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs